Crescita Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Crescita Therapeutics şirketinin toplam hissedar öz sermayesi CA$17.2M ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$23.0M ve CA$5.8M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$9.01m
Eşitlik	CA$17.20m
Toplam yükümlülükler	CA$5.76m
Toplam varlıklar	CA$22.95m

Son finansal sağlık güncellemeleri

Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Nov 18

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)

Oct 25

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

May 30

Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Jan 04

Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Nov 18

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

May 05

Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CTX 'nin kısa vadeli varlıkları ( CA$17.0M ) kısa vadeli yükümlülüklerini ( CA$5.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: CTX şirketinin kısa vadeli varlıkları ( CA$17.0M ) uzun vadeli yükümlülüklerini ( CA$695.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CTX borçsuzdur.

Borcun Azaltılması: CTX şirketinin 5 yıl önce borç/öz sermaye oranı 20.5% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CTX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: CTX tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Crescita Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)

Second quarter 2024 earnings released: CA$0.048 loss per share (vs CA$0.014 loss in 2Q 2023)

Crescita Therapeutics Inc. (TSX:CTX) completed the acquisition of Assets of Occy Laboratory for CAD 0.9 million.

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

First quarter 2024 earnings released: CA$0.032 loss per share (vs CA$0.013 loss in 1Q 2023)

Crescita Therapeutics Inc., Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: CA$0.098 loss per share (vs CA$0.042 profit in FY 2022)

Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Chief Financial Officer recently bought CA$52k worth of stock

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: CA$0.063 loss per share (vs CA$0.009 profit in 3Q 2022)

New major risk - Market cap size

Second quarter 2023 earnings released: CA$0.014 loss per share (vs CA$0.002 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.013 loss per share (vs CA$0.023 loss in 1Q 2022)

Full year 2022 earnings released: EPS: CA$0.042 (vs CA$0.053 loss in FY 2021)

Third quarter 2022 earnings released: EPS: CA$0.009 (vs CA$0.043 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.035 loss in 2Q 2021)

First quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.021 loss in 1Q 2021)

Crescita Therapeutics Inc., Annual General Meeting, May 12, 2022

High number of new directors

Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Third quarter 2021 earnings released: CA$0.043 loss per share (vs CA$0.20 profit in 3Q 2020)

Crescita Therapeutics Inc. (TSX : CTX) acquired minority stake in Akyucorp Ltd. for CAD 0.32 million.

Second quarter 2021 earnings released: CA$0.035 loss per share (vs CA$0.15 loss in 2Q 2020)

Independent Director has left the company

First quarter 2021 earnings released: CA$0.021 loss per share (vs CA$0.024 loss in 1Q 2020)

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

Full year 2020 earnings released: EPS CA$0.002 (vs CA$0.089 in FY 2019)

Full year 2020 earnings released: EPS CA$0.002 (vs CA$0.089 in FY 2019)

Crescita Therapeutics Inc., Annual General Meeting, May 11, 2021

Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

New 90-day high: CA$0.89

Crescita Announces Filing of New Medical Device License

New 90-day high: CA$0.86

Third quarter 2020 earnings released: EPS CA$0.20

Crescita Therapeutics Inc. Announces Licensing Agreement for Pliaglis in China

New 90-day low: CA$0.45

Earnings released

New 90-day low - CA$0.46

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin